Overview

Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML

Status:
Recruiting
Trial end date:
2031-12-31
Target enrollment:
Participant gender:
Summary
It is a randomized phase 3 study comparing two conditioning regimens in children with Acute Myeloid Leukemia, AML, undergoing allogenic stem cell transplantation. The primary aim is to investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade III to IV-free, chronic non-limited GvHD-free, relapse free survival than a conditioning regimen combining three alkylating agents (BuCyMel)
Phase:
Phase 3
Details
Lead Sponsor:
Vastra Gotaland Region
Treatments:
Busulfan
Clofarabine
Cyclophosphamide
Fludarabine
Melphalan